Live biotherapeutic products (LBPs) are regulated as drugs by the FDA and range from single microbes with defined pharmacological properties to entire ecosystems that can prevent and treat infection. Our ‘living medicines’ have extensive safety data in a human population, target conditions that impact large global communities, and can be clinically validated at a fraction of the cost of a small molecule.
Live biotherapeutics to protect against vaginal dysbiosis and restore homeostatic function to the vaginal microbiome.
“Living medicines will disrupt the way we approach many diseases—and in some cases, may even replace the primary standard of care. By targeting these pervasive, unmet medical needs, especially in areas that have experienced little to no innovation, we can move toward a new future in global women’s health.” ● Dr. Jacques Ravel, Chief Scientist
Jacques Ravel PhD
Major Depressive Disorder (MDD)
Live biotherapeutics with defined biological activity that modulate the gut-brain axis.
Irritable Bowel Syndrome
Rationally defined microbial consortia for reproducibly improving quality of life in Irritable Bowel Syndrome.
Dyslipidemia (High Cholesterol)
Live biotherapeutic to modulate host cholesterol levels via bile salt hydrolase activity.